Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.59 USD | +1.85% | -2.97% | -36.57% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.57% | 186M | |
+7.94% | 217B | |
+15.44% | 195B | |
+31.15% | 112B | |
+3.76% | 65.83B | |
+13.69% | 52.67B | |
+4.70% | 49.86B | |
-3.73% | 38.18B | |
-0.25% | 35.39B | |
+23.79% | 31.02B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M